Pharma group dealt another blow following decision by British to award vaccine contract to rival Pfizer
Vaccine maker to seek approval for jab as it tries to diversify product pipeline
As Covid revenues slump, technology developed to fight the pandemic is having some success combating this disease
So-called FLiRT strains set to test effectiveness of vaccines against latest mutations
Decision is a boon for the mRNA-vaccine maker in its legal fight to recoup pandemic profits from rivals
Agreement worth up to $1.2bn includes plan for combined flu and Covid shots
Saving humanity’s a costly business
Anglo-Swedish drugmaker says availability of newer vaccines hit demand for jab
Xi Jinping hopes manufacturing can offset the property slump
Moderna alleges Pfizer and BioNTech infringed its patents in use of mRNA platform
Shah Capital wants change in US biotech’s strategy as its shares have tumbled since their pandemic peak
Pledges to invest in pandemic preparedness with facility in Kenya fall short as sales of Covid jabs decline
Not only is the cost-benefit ratio unbeatable, but not to undertake this spending is to court disaster
Officials warn weaknesses in surveillance will hinder vaccine development as countries struggle to agree accord
We risk forgetting the lessons of the Covid pandemic
Better awareness and access are needed to rebuild measles vaccination rates
A trial of $3 payments for getting a Covid jab in rural Ghana offers a game-changing way to meet public health goals
Americans’ interest in vaccinations has flagged despite efforts to boost uptake of latest jab
Vaccine recipient claims he suffered side effect of severe blood clot
Covid may have abated, but emerging diseases and new drug categories are keeping the analytics firm busy
German group slashes guidance by €1bn and reduces spending as it expects fewer first vaccine doses and lower boosting
Biotech blames weaker US sales after lowering full-year forecast
Call for rapid detection comes as pharma groups criticise draft WHO treaty on how to avoid another health crisis
Biotech group hit by lower demand, with majority of write-offs relating to raw materials bought during pandemic
US biotech has been struggling to overcome fall in demand for coronavirus jabs
International Edition